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abstract
Epithelial-mesenchymal transition (EMT) is a process by 
which a fully differentiated epithelial cell attains mesenchymal 
traits and capabilities such as motility and invasiveness. There are 
three types. Type 3 EMT is associated with tumour cells increasing 
their malignant potential and result in increased resistance to 
conventional chemo- and radiotherapy. Molecules involved are 
being used as biomarkers and therapeutic targets.
dEfining EMt 
EMT refers to the biological process by which epithelial cells 
become mesenchymal cells. During this transition, epithelial 
cells undergo several biochemical and cytoskeletal modifications. 
Epithelial cells are polarised cells with distinct apical, lateral and 
basal plasma membrane domains. They are characterised by 
intercellular adhesion complexes. Upon undergoing EMT, the 
apico-basal polarity is lost, the intercellular adhesion complexes are 
disrupted, and the underlying basement membrane is degraded. 
The resulting mesenchymal cells are nonpolarised, lack intercellular 
junctions, and are able to migrate away through the extracellular 
matrix as individual cells from the epithelial layer in which they 
originated1,2.
EMT was first described by Elizabeth Hay3, who realised that 
the phenotypic conversion of epithelial cells was important during 
early embryo cell migration and gastrulation. She suggested that 
differentiated epithelial cells can “transform” into mesenchymal 
cells by undergoing phenotypic changes. Since then, studies have 
found that EMT is reversible, and mesenchymal cells can go back to 
epithelial cells through a reverse process of mesenchymal-epithelial 
transition (MET). For this reason, “transformation” has been 
amended to “transition”3,4.
Three subtypes of EMT are encountered. Type 1 EMT is 
associated with implantation, embryo formation, and organ 
development. Type 2 EMT is associated with organ fibrosis, tissue 
regeneration, and wound healing5-7. Type 3 EMT occurs in epithelial 
cancer cells that have formed solid tumours. Here, EMT is linked in 
the switching of epithelial cells into metastatic cells which journey in 
the bloodstream and then form secondaries8.
EMt and its rolE in cancEr progrEssion and MEtastasis
Several molecular processes are employed to initiate and complete 
an EMT. Some of these processes include changes in the expression 
of (a) specific cell-surface proteins, (b) cytoskeletal proteins, (c) 
extracellular proteins, (d) transcription factors, and (d) specific 
microRNAs. 
(a) ExprEssion of spEcific cEll-surfacE protEins 
E-cadherin: E-cadherin expression has been found to decrease 
during EMT9. Indeed, the induction of EMT in cancer is promoted 
by a loss of function of E-cadherin10. Cell lines that lack E-cadherin 
are more prone to increased tumourigenicity and metastasis when 
transferred into mice that are immunodeficient11. Mutations in the 
E-cadherin gene were identified in gastric cancers in patients under 
35 years12 and in the signet ring cell carcinoma of the stomach13. 
Bringuier et al showed that decreased E-cadherin correlates with 
a poor prognosis in bladder tumours14. A similar relationship 
was shown by Mattijssen et al in head and neck squamous-cell 
carcinoma15.
Integrins: Studies show that integrin signalling facilitates 
EMT16,17. However, some integrins are expressed on both epithelial 
and mesenchymal cells, and so they have limited use as biomarkers. 
Still, some can be used as EMT markers, e.g. (i) β6 integrin – in colon 
carcinoma, only cancer cells that have metastatic potential express 
high levels; normal epithelial cells and non-invasive tumour cells 
express low levels18; (ii) α5 integrin increase expression in B16F10 
melanoma cells19.
Discoidin Domain Receptor 2 (DDR2): DDR2 is a marker 
that reflects adjustment to the changed microenvironment of the 
extracellular matrix as a result of EMT. Expression of this collagen-
specific receptor tyrosine kinase is associated with increased 
invasiveness20,21.
(b) ExprEssion of cytosKElEtal protEins 
FSP1: Fibroblast-Specific Protein-1 is used as a biomarker for the 
detection of Type 3 EMT22,23. Indeed, as part of the molecular program 
of Type 3 EMT, metastatic cells express FSP1. Expression of FSP1 in 
tumour cells could determine the latency of tumour dispersion and 
it could be an appropriate therapeutic target to control metastatic 
progression22.
Vimentin: Vimentin is an intermediate filament expressed in 
mesenchymal cells. There is a positive relationship between vimentin 
expression and increased metastasis in infiltrating ductal breast 
carcinoma24. In their study, Raymond and Leong state that vimentin 
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expression could be a marker of aggressive behaviour and such 
carcinomas may profit from early adjuvant therapy. This is 
reiterated in a review by Kokkinos et al25.
α-SMA: Alpha-smooth muscle actin is used as a biomarker 
in breast cancers especially basal phenotype or basal-like breast 
cancers26, which are characterised by early recurrence and 
decreased overall survival27.
β-Catenin: In normal epithelial cells and non-invasive cancer 
cells, β-Catenin is found located in the cell membranes. In cells 
that are undergoing EMT, however, β-Catenin is located either in 
the cytoplasm or in the nucleus28. Here, it plays a dual role – it links 
cadherins to the cytoskeleton, and, together with the T cell factor 
(TCF)/LEF, it serves as a co-transcriptional activator29. In fact, 
the resulting complex, the β-Catenin/TCF/LEF complex, directly 
controls gene expression that is associated with EMT, particularly 
Snail130. For this reason, β-Catenin is used as a biomarker of EMT 
in various studies of cancer. Brabletz et al investigated the nuclear 
overexpression of β-Catenin in colorectal cancer, and found that 
the nuclear translocation of β-Catenin may play a direct role in the 
tumour invasion processes28.
(c) ExprEssion of ExtracEllular protEins 
Laminins: Certain laminins have become established 
biomarkers. For instance, the upregulation of laminin-5 
is associated with invasive cancers, such as oral squamous 
carcinoma31, hepatocellular carcinoma32, and breast carcinomas of 
the ductal type33.
Fibronectin: Fibronectin is an integral constituent of the 
extracellular matrix associated with the desmoplastic stroma in 
tumours. However, its use as a biomarker is limited because it is 
also produced by other types of cells, such as epithelial cells34. Still, 
some studies have found that Type 3 EMT is associated with an 
increase of fibronectin expression in vitro35.
(d) actiVation of transcription factors 
FTS-1: Fibroblast transcription site–1 is a regulatory element 
that is present in the promoter region of various genes associated 
with EMT, including those that encode α-SMA, β-Catenin, 
E-cadherin, FSP1, vimentin, Snail1 and Twist. In addition, FTS-1 
forms a complex with CBF-A and KRAB-associated protein 1 
(KAP-1)7; the resulting CBF-A/KAP-1/FTS-1 complex is a master 
regulator of EMT36.
Snail: Several studies37-9 have shown that the transcription 
factor Snail mediates EMT. Indeed, all known events occurring 
appear to be associated with the activation of Snail. Amongst 
others, Snail activation brings about the suppression of E-cadherin 
expression and the increased expression of mesenchymal cell 
markers such as fibronectin40. A correlation between Snail 
activation and EMT was established in human colorectal cancer 
cells37, in oral squamous carcinoma cells38, and in thyroid cancer 
cells39.
Studies, such as those by Medici et al41, have also demonstrated 
that Snail-mediated EMTs are promoted by the transforming 
growth factor-β (TGF-β). Separate in vitro studies have shown that 
TGF-β can induce EMT in certain types of cancers such as breast42, 
ovarian43 and skin cancers44.
Twist: Twist is a protein that is upregulated during cancer 
metastasis. Specifically, Twist acts independently of Snail to repress 
E-cadherin45 and to upregulate fibronectin and N-cadherin35.
FOXC2: Forkhead boxC2 is another transcription factor. 
Overexpression of any inducer of EMT (e.g. Snail, TGF-β, Twist) 
increases expression of FOXC2. Overexpression of FOXC2 itself 
induces EMT, suggesting a significant role for FOXC2 in Type 3 EMT, 
especially when ductal breast cancers and metastatic breast cancer 
cells are involved46.
(E) changEs in thE ExprEssion of spEcific micrornas 
The fact that EMT is reversible, suggests that EMT can also have 
an epigenetic background. Non-coding microRNAs are the ones 
most documented and form components of the cellular signalling 
circuitry choreographing the EMT program7. miR200 was found to 
inhibit the transcriptional repressors of E-cadherin expression, ZEB1 
(zinc finger E-box binding homeobox 1) and ZEB2, and thus helps in 
preserving the epithelial cell phenotype47,48. miR200 have been found 
to be downregulated in ductal and metaplastic breast cancers, where a 
loss of miR200 is correlated with increased vimentin expression and a 
decrease in E-cadherin levels in cancer cells47. 
In addition there is also miR21 and miR-10b; TGF-β1–induced 
EMT involving keratinocytes is associated with miR2149 and Twist-
induced EMT, involving breast cancer cells, is associated with miR-
10b50. 
thEranostic iMplications 
Many of the aforementioned molecules are being used as 
biomarkers to assess the presence or severity of cancer and its 
response to medical treatment. They are also being used to optimize 
therapy for individual patients. Furthermore, clinical studies based on 
EMT mechanisms have started.
One study by Chang et al 51 showed that radio-resistance in 
prostate cancer is associated with EMT events and the PI3K/Akt/
mTOR signaling pathway. The in vitro tests carried out showed 
that the combination of BEZ235 (PI3K/mTOR inhibitor) with 
radiotherapy is a promising approach to overcome radio-resistance 
in the treatment of prostate cancer. This modality leads to reduced 
expression of EMT markers and PI3K/Akt/mTOR signaling pathway 
proteins. Such findings have laid down a platform for in vivo animal 
studies and clinical trials.
Another showcase is the work by Cufi et al52 which showed that 
silibinin (from thistle extract) reversed levels of certain microRNAs 
associated with EMT and repressed mesenchymal-related markers in 
NSCLC (non-small cell lung cancer) refractory to erlotinib treatment. 
Silibinin was also found to activate a mesenchymal-to-epithelial 
transition (MET) and prevent the extremely migratogenic phenotype. 
Now clinical trials are on the way to assess how silibinin might be 
useful to prevent or reverse NSCLC progression after treatment with 
erlotinib. 
conclusion
Even though some insight into the mechanisms involved in 
EMT in cancer progression and metastasis has been achieved, more 
research is warranted so that the knowledge gained can be translated 
into coherent, clinically effective systems.  
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